Article Cited by others

RESEARCH

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

Houben Roland, Becker Jurgen C, Kappel Andreas, Terheyden Patrick, Brocker Eva-B, Goetz Rudolf, Rapp Ulf R

Year : 2004| Volume: 3| Issue : 1 | Page no: 6-6

   This article has been cited by
 
1 Mapping normal and cancer cell signalling networks: Towards single-cell proteomics
Irish, J.M., Kotecha, N., Nolan, G.P.
Nature Reviews Cancer. 2066; 6(2): 146-155
[Pubmed]  [Google Scholar]
2 Targeting BRAF for patients with melanoma
Arkenau, H.-T., Kefford, R., Long, G.V.
British Journal of Cancer. 2011; 104(3): 392-398
[Pubmed]  [Google Scholar]
3 Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
Long, G.V., Menzies, A.M., Nagrial, A.M., Haydu, L.E., Hamilton, A.L., Mann, G.J., Hughes, T.M., (...), Kefford, R.F.
Journal of Clinical Oncology. 2011; 29(10): 1239-1246
[Pubmed]  [Google Scholar]
4 Prospects for non-immunological molecular therapeutics in melanoma
Eustace, A.J., Mahgoub, T., Tryfonopoulos, D., OæDonovan, N., Crown, J.
Journal of B.U.ON.. 2010; 15(1): 9-18
[Pubmed]  [Google Scholar]
5 NRAS mutations are rare in colorectal cancer
Irahara, N., Baba, Y., Nosho, K., Shima, K., Yan, L., Dias-Santagata, D., Iafrate, A.J., (...), Ogino, S.
Diagnostic Molecular Pathology. 2010; 19(3): 157-163
[Pubmed]  [Google Scholar]
6 Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications
Kyrgidis, A., Tzellos, T.-G., Triaridis, S.
Journal of Carcinogenesis. 2010; 9(art 3)
[Pubmed]  [Google Scholar]
7 Metastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation
Rozenberg, G.I., Monahan, K.B., Torrice, C., Bear, J.E., Sharpless, N.E.
Melanoma Research. 2010; 20(5): 361-371
[Pubmed]  [Google Scholar]
8 Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells
Kong, Y., Kumar, S.M., Xu, X.
Archives of Pathology and Laboratory Medicine. 2010; 134(12): 1740-1749
[Pubmed]  [Google Scholar]
9 C-Raf is associated with disease progression and cell proliferation in a subset of melanomas
Jilaveanu, L.B., Zito, C.R., Aziz, S.A., Conrad, P.J., Schmitz, J.C., Sznol, M., Camp, R.L., (...), Kluger, H.M.
Clinical Cancer Research. 2009; 15(18): 5704-5713
[Pubmed]  [Google Scholar]
10 Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition
Yang, J., Price, M.A., Gui, Y.L., Bar-Eli, M., Salgia, R., Jagedeeswaran, R., Carlson, J.H., (...), McCarthy, J.B.
Cancer Research. 2009; 69(19): 7538-7547
[Pubmed]  [Google Scholar]
11 Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif
Moretti, S., De Falco, V., Tamburrino, A., Barbi, F., Tavano, M., Avenia, N., Santeusanio, F., (...), Puxeddu, E.
Biochimica et Biophysica Acta - Molecular Cell Research. 2009; 1793(11): 1634-1645
[Pubmed]  [Google Scholar]
12 Molecular pathways supporting the proliferation staging of malignant melanoma (Review)
Quatresooz, P., Pierard, G.E., Pierard-Franchimont, C., Arrese, J.E., Blaise, G., Bourguignon, R., Braham, C., (...), Willemaers, V.
International Journal of Molecular Medicine. 2009; 24(3): 295-301
[Pubmed]  [Google Scholar]
13 Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas
Kotoula, V., Sozopoulos, E., Litsiou, H., Fanourakis, G., Koletsa, T., Voutsinas, G., Tseleni-Balafouta, S., (...), Mitsiades, N.
Endocrine-Related Cancer. 2009; 16(2): 565-572
[Pubmed]  [Google Scholar]
14 Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma
Greene, V.R., Johnson, M.M., Grimm, E.A., Ellerhorst, J.A.
Journal of Investigative Dermatology. 2009; 129(6): 1483-1488
[Pubmed]  [Google Scholar]
15 RAF expression in human astrocytic tumors
Hagemann, C., Gloger, J., Anacker, J., Said, H.M., Gerngras, S., Künhel, S., Meyer, C., (...), Vince, G.H.
International Journal of Molecular Medicine. 2009; 23(1): 17-31
[Pubmed]  [Google Scholar]
16 Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation
Houben, R., Ortmann, S., Drasche, A., Troppmair, J., Herold, M.J., Becker, J.C.
Journal of Investigative Dermatology. 2009; 129(2): 406-414
[Pubmed]  [Google Scholar]
17 Primary dermal melanoma: A case report and molecular characterization
Hida, Y., Kubo, Y., Miyajima, O., Arase, S.
Journal of Dermatology. 2009; 36(6): 346-352
[Pubmed]  [Google Scholar]
18 BRAF Signaling and Targeted Therapies in Melanoma
Dhomen, N., Marais, R.
Hematology/Oncology Clinics of North America. 2009; 23(3): 529-545
[Pubmed]  [Google Scholar]
19 Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma
Jovanovic, B., Kröckel, D., Linden, D., Nilsson, B., Egyhazi, S., Hansson, J.
Journal of Investigative Dermatology. 2008; 128(11): 2696-2704
[Pubmed]  [Google Scholar]
20 Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma
Houben, R., Vetter-Kauczok, C.S., Ortmann, S., Rapp, U.R., Broecker, E.B., Becker, J.C.
Journal of Investigative Dermatology. 2008; 128(8): 2003-2012
[Pubmed]  [Google Scholar]
21 Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J.T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., (...), Bollag, G.
Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(8): 3041-3046
[Pubmed]  [Google Scholar]
22 Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma
Akslen, L.A., Puntervoll, H., Bachmann, I.M., Straume, O., Vuhahula, E., Kumar, R., Molven, A.
Melanoma Research. 2008; 18(1): 29-35
[Pubmed]  [Google Scholar]
23 p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors
Gallagher, S.J., Thompson, J.F., Indsto, J., Scurr, L.L., Lett, M., Gao, B.-F., Dunleavey, R., (...), Rizos, H.
Neoplasia. 2008; 10(11): 1231-1239
[Pubmed]  [Google Scholar]
24 BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC
Schrama, D., Keller, G., Houben, R., Ziegler, C.G., Vetter-Kauczok, C.S., Ugurel, S., Becker, J.C.
Journal of Carcinogenesis. 2008; 7(Art 1)
[Pubmed]  [Google Scholar]
25 Construction and expression of eukaryotic expression vector for human wild-type and V600E mutant BRAF gene
Cheng, Z.-J., Shi, X., Tang, Y.-H., Gao, N.-R.
World Chinese Journal of Digestology. 2008; 16(21): 2395-2398
[Pubmed]  [Google Scholar]
26 In melanocytic lesions the fraction of BRAFV600E alleles is associated with sun exposure but unrelated to ERK phosphorylation
Venesio, T., Chiorino, G., Balsamo, A., Zaccagna, A., Petti, C., Scatolini, M., Pisacane, A., (...), Risio, M.
Modern Pathology. 2008; 21(6): 716-726
[Pubmed]  [Google Scholar]
27 Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site
Platz, A., Egyhazi, S., Ringborg, U., Hansson, J.
Molecular Oncology. 2008; 1(4): 395-405
[Pubmed]  [Google Scholar]
28 Understanding signaling cascades in melanoma
Lopez-Bergami, P., Fitchman, B., Ronai, Z.
Photochemistry and Photobiology. 2008; 84(2): 289-306
[Pubmed]  [Google Scholar]
29 Gene expression profiling and clinical outcome in melanoma: In search of novel prognostic factors
Winnepenninckx, V., van den Oord, J.J.
Expert Review of Anticancer Therapy. 2007; 7(11): 1611-1631
[Pubmed]  [Google Scholar]
30 Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma
Terheyden, P., Hofmann, M.A., Weininger, M., Bröcker, E.-B., Becker, J.C.
Journal of Cancer Research and Clinical Oncology. 2007; 133(11): 897-901
[Pubmed]  [Google Scholar]
31 Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors
Strumberg, D., Clark, J.W., Awada, A., Moore, M.J., Richly, H., Hendlisz, A., Hirte, H.W., (...), Schwartzh, B.
Oncologist. 2007; 12(4): 426-437
[Pubmed]  [Google Scholar]
32 Toward a molecular classification of melanoma
Fecher, L.A., Cummings, S.D., Keefe, M.J., Alani, R.M.
Journal of Clinical Oncology. 2007; 25(12): 1606-1620
[Pubmed]  [Google Scholar]
33 New insight into BRAF mutations in cancer
Dhomen, N., Marais, R.
Current Opinion in Genetics and Development. 2007; 17(1): 31-39
[Pubmed]  [Google Scholar]
34 Disruption of Tumor Cell Adhesion Promotes Angiogenic Switch and Progression to Micrometastasis in RAF-Driven Murine Lung Cancer
Ceteci, F., Ceteci, S., Karreman, C., Kramer, B.W., Asan, E., Götz, R., Rapp, U.R.
Cancer Cell. 2007; 12(2): 145-159
[Pubmed]  [Google Scholar]
35 Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients
Daniotti, M., Vallacchi, V., Rivoltini, L., Patuzzo, R., Santinami, M., Arienti, F., Cutolo, G., (...), Rodolfo, M.
International Journal of Cancer. 2007; 120(11): 2439-2444
[Pubmed]  [Google Scholar]
36 Novel inhibitors in the treatment of metastatic melanoma
Kalinsky, K., Haluska, F.G.
Expert Review of Anticancer Therapy. 2007; 7(5): 715-724
[Pubmed]  [Google Scholar]
37 Molecular targeted therapy of melanoma
Houben, R., Ortmann, S., Schrama, D., Bröcker, E.-B., Becker, J.C.
Giornale Italiano di Dermatologia e Venereologia. 2007; 142(2): 161-170
[Pubmed]  [Google Scholar]
38 Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy
Shinozaki, M., OæDay, S.J., Kitago, M., Amersi, F., Kuo, C., Kim, J., Wang, H.-J., Hoon, D.S.B.
Clinical Cancer Research. 2007; 13(7): 2068-2074
[Pubmed]  [Google Scholar]
39 B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis
Ugurel, S., Thirumaran, R.K., Bloethner, S., Gast, A., Sucker, A., Mueller-Berghaus, J., Rittgen, W., (...), Schadendorf, D.
PLoS ONE. 2007; 2(2): e236
[Pubmed]  [Google Scholar]
40 NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: A study based on mutation screening by pyrosequencing
Edlundh-Rose, E., Egyházi, S., Omholt, K., Månsson-Brahme, E., Platz, A., Hansson, J., Lundeberg, J.
Melanoma Research. 2006; 16(6): 471-478
[Pubmed]  [Google Scholar]
41 Absence of classical MAP kinase pathway signalling in merkel cell carcinoma
Houben, R., Michel, B., Vetter-Kauczok, C.S., Pföhler, C., Laetsch, B., Wolter, M.D., Leonard, J.H., (...), Becker, J.C.
Journal of Investigative Dermatology. 2006; 126(5): 1135-1142
[Pubmed]  [Google Scholar]
42 Identification of inhibitors of the kinase activity of oncogenic V600EBRAF in an enzyme cascade high-throughput screen
Newbatt, Y., Burns, S., Hayward, R., Whittaker, S., Kirk, R., Marshall, C., Springer, C., (...), Aherne, W.
Journal of Biomolecular Screening. 2006; 11(2): 145-154
[Pubmed]  [Google Scholar]
43 A trip through the signaling pathways of melanoma | [Ein streifzug durch die (signal-)wege des malignen melanoms]
Fensterle, J.
JDDG - Journal of the German Society of Dermatology. 2006; 4(3): 205-217
[Pubmed]  [Google Scholar]
44 Molecularly targeted therapy for melanoma: Current reality and future options
Becker, J.C., Kirkwood, J.M., Agarwala, S.S., Dummer, R., Schrama, D., Hauschild, A.
Cancer. 2006; 107(10): 2317-2327
[Pubmed]  [Google Scholar]
45 Raf kinases: Oncogenesis and drug discovery
Schreck, R., Rapp, U.R.
International Journal of Cancer. 2006; 119(10): 2261-2271
[Pubmed]  [Google Scholar]
46 High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi
Ichii-Nakato, N., Takata, M., Takayanagi, S., Takashima, S., Lin, J., Murata, H., Fujimoto, A., (...), Saida, T.
Journal of Investigative Dermatology. 2006; 126(9): 2111-2118
[Pubmed]  [Google Scholar]
47 BRAF somatic mutations in malignant melanoma and melanocytic naevi
Thomas, N.E.
Melanoma Research. 2006; 16(2): 97-103
[Pubmed]  [Google Scholar]
48 Melanoma genetics and the development of rational therapeutics
Chudnovsky, Y., Khavari, P.A., Adams, A.E.
Journal of Clinical Investigation. 2005; 115(4): 813-824
[Pubmed]  [Google Scholar]
49 Absence of mutations in the coding sequence of the potential tumor suppessor 3pK in metastatic melanoma
Houben, R., Becker, J.C., Rapp, U.R.
Journal of Carcinogenesis. 2005; 4(Art 23)
[Pubmed]  [Google Scholar]
50 Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF
Emuss, V., Garnett, M., Mason, C., Marais, R.
Cancer Research. 2005; 65(21): 9719-9726
[Pubmed]  [Google Scholar]
51 Human malignant melanoma: Detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis
Willmore-Payne, C., Holden, J.A., Tripp, S., Layfield, L.J.
Human Pathology. 2005; 36(5): 486-493
[Pubmed]  [Google Scholar]
52 Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization
Garnett, M.J., Rana, S., Paterson, H., Barford, D., Marais, R.
Molecular Cell. 2005; 20(6): 963-969
[Pubmed]  [Google Scholar]
53 Cutaneous melanoma susceptibility and progression genes
De Snoo, F.A., Hayward, N.K.
Cancer Letters. 2005; 230(2): 153-186
[Pubmed]  [Google Scholar]
54 Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi
Papp, T., Schipper, H., Kumar, K., Schiffmann, D., Zimmermann, R.
Melanoma Research. 2005; 15(5): 401-407
[Pubmed]  [Google Scholar]
55 Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma
Zhuang, L., Lee, C.S., Scolyer, R.A., McCarthy, S.W., Palmer, A.A., Zhang, X.D., Thompson, J.F., (...), Hersey, P.
Journal of Clinical Pathology. 2005; 58(11): 1163-1169
[Pubmed]  [Google Scholar]
56 Expression of activated Akt and PTEN in malignant Melanomas: Relationship with clinical outcome
Slipicevic, A., Holm, R., Nguyen, M.T.P., Bøhler, P.J., Davidson, B., Flørenes, V.A.
American Journal of Clinical Pathology. 2005; 124(4): 528-536
[Pubmed]  [Google Scholar]
57 Kinase inhibitors for the therapy of malignant melanoma | [Kinaseinhibitoren zur therapie des malignen melanoms]
Becker, J.C., Schrama, D., Bröcker, E.-B., Houben, R.
JDDG - Journal of the German Society of Dermatology. 2005; 3(10): 762-767
[Pubmed]  [Google Scholar]
58 BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival
Akslen, L.A., Angelini, S., Straume, O., Bachmann, I.M., Molven, A., Hemminki, K., Kumar, R.
Journal of Investigative Dermatology. 2005; 125(2): 312-317
[Pubmed]  [Google Scholar]
59 Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas
Takata, M., Goto, Y., Ichii, N., Yamaura, M., Murata, H., Koga, H., Fujimoto, A., Saida, T.
Journal of Investigative Dermatology. 2005; 125(2): 318-322
[Pubmed]  [Google Scholar]
60 Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival
Grafström, E., Egyhézi, S., Ringborg, U., Hansson, J., Platz, A.
Clinical Cancer Research. 2005; 11(8): 2991-2997
[Pubmed]  [Google Scholar]
61 The role of B-RAF in melanoma
Gray-Schopfer, V.C., Da Rocha Dias, S., Marais, R.
Cancer and Metastasis Reviews. 2005; 24(1): 165-183
[Pubmed]  [Google Scholar]
62 Clinical significance of BRAF mutations in metastatic melanoma
Chang, D.Z., Panageas, K.S., Osman, I., Polsky, D., Busam, K., Chapman, P.B.
Journal of Translational Medicine. 2004; 2
[Pubmed]  [Google Scholar]
63 Genetic progression of metastatic melanoma
Rodolfo, M., Daniotti, M., Vallacchi, V.
Cancer Letters. 2004; 214(2): 133-147
[Pubmed]  [Google Scholar]
64 Loitering with intent: New evidence for the role of BRAF mutations in the proliferation of melanocytic lesions
Smalley, K.S.M., Herlyn, M.
Journal of Investigative Dermatology. 2004; 123(4): xvi-xvii
[Pubmed]  [Google Scholar]
65 Guilty as charged: B-RAF is a human oncogene
Garnett, M.J., Marais, R.
Cancer Cell. 2004; 6(4): 313-319
[Pubmed]  [Google Scholar]
66 B-Raf specific antibody responses in melanoma patients
Fensterle, J., Becker, J.C., Potapenko, T., Heimbach, V., Vetter, C.S., Bröcker, E.B., Rapp, U.R.
BMC Cancer. 2004; 4(62)
[Pubmed]  [Google Scholar]
67 Immunogenicity of constitutively active V599EBRaf
Andersen, M.H., Fensterle, J., Ugurel, S., Reker, S., Houben, R., Guldberg, P., Berger, T.G., (...), Becker, J.C.
Cancer Research. 2004; 64(15): 5456-5460
[Pubmed]  [Google Scholar]
68 Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis
Sparmann, A., Bar-Sagi, D.
Cancer Cell. 2004; 6(5): 447-458
[Pubmed]  [Google Scholar]
69 The RAF proteins take centre stage
Wellbrock, C., Karasarides, M., Marais, R.
Nature Reviews Molecular Cell Biology. 2004; 5(11): 875-885
[Pubmed]  [Google Scholar]

 

Read this article